Investor Relations

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Investor Relations

KemPharm uses its LAT™ Technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.

 

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.
CELEBRATION, Fla. , July 21, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced the U.S. commercial launch of AZSTARYS™, a once-daily product for the treatment of attention
Toggle Summary KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
CELEBRATION, Fla. , June 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced it has entered into agreements with certain of its holders of its existing warrants exercisable
Toggle Summary KemPharm Issues Letter to Shareholders
CELEBRATION, Fla. , June 16, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders
Toggle Summary KemPharm to be Added to Russell 2000® and Russell 3000® Indexes Effective June 28, 2021
CELEBRATION, Fla. , June 09, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today its expected addition to the broad-market Russell 3000 ®  Index and the Russell 2000 ®  Index in

View more

Upcoming Events

There are currently no events to display.

View more

Letter to Shareholders

Travis C. Mickle, Ph.D.
Chairman, President, Chief Executive Officer and Shareholder
KemPharm, Inc.

Download